Toll-like receptor (TLR) 2 specific and antagonistic monoclonal antibody

TLR2 represents an “earliest possible” target for prevention and therapeutic

intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.

Further Information: PDF

Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000

Contact
Dr. Wolfgang Knappe

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

A universal framework for spatial biology

SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…

How complex biological processes arise

A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…

Airborne single-photon lidar system achieves high-resolution 3D imaging

Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…

Partners & Sponsors